Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET

Company Participants

Jenna Cohen - VP, IR

Kate Haviland - CEO

Philina Lee - CCO

Fouad Namouni - President, R&D

Mike Landsittel - CFO

Christy Rossi - COO

Becker Hewes - CMO

Conference Call Participants

Brad Canino - Stifel

Dane Leone - Raymond James

Reni Benjamin - JMP Securities

Eun Yang - Jefferies

Marc Frahm - TD Cowen

Salveen Richter - Goldman Sachs

Michael Schmidt - Guggenheim Partners

Ami Fadia - Needham

Mike Ulz - Morgan Stanley

Matt Biegler - Oppenheimer

Peter Lawson - Barclays

Derek Archila - Wells Fargo

David Lebowitz - Citi

Joel Beatty - Baird

Operator

Good morning, ladies and gentlemen. My name is Glen. I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines Second Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions].

I will now turn it to Jenna Cohen, Vice President of Investor Relations to begin.

Jenna Cohen

Thank you, Glen. Good morning, everyone and welcome to Blueprint Medicines second quarter 2023 financial and operating results conference call.

This morning, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release, as well as the slides that we'll be reviewing today by going to the Investor section of our website at www.blueprintmedicines.com.

Joining me today are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer; Fouad Namouni, President, Research & Development; and Mike Landsittel, Chief Financial Officer. Christy Rossi, Chief Operating Officer and Becker Hewes, Chief Medical Officer will also be available for Q&A.

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements as outlined on Slide 3 and are subject to a number of risks and uncertainties. These may cause our actual results to differ materially, including those described in our reports filed with the SEC. You're cautioned not to place any undue reliance on these forward-looking statements and Blueprint disclaims any obligation to update such statements.

I'll now hand the call over to Kate.

Kate Haviland

Thank you, Jenna, and good morning, everyone.

In the second quarter, we entered a new era of Blueprint Medicines, which we call precision at scale. This inflection is driven by significant near-term growth opportunity for AYVAKIT with the recent FDA approval and ISM. With AYVAKIT, ISM patients now have the first and only medicine approved to treat their disease, and importantly, a medicine that was specifically designed to stop ISM at its source.